In this interview with Small Caps, Archer Materials discusses its progress in advancing quantum technologies and biochip development on the company’s carbon materials platform.
Archer is the only ASX-listed company focused on developing both quantum semiconductors and biochip technologies, with a capital-light intellectual property model designed to support commercial partnerships and licensing opportunities.
The discussion outlines the fundamentals of Archer’s materials platform and explains why the company is developing biochips and quantum technologies in parallel, targeting applications across healthcare diagnostics, computing and sensing.
The interview also explores Archer’s collaborations with leading research organisations including IMEC and CSIRO, the company’s approach to commercialisation, and potential pathways to partner with major global technology and healthcare companies.
Archer also highlights key milestones and developments expected through 2026, as it continues advancing its technologies toward real-world deployment.
Get the latest updates on our breakthrough technologies and research developments. Join thousands of researchers, investors, and technology enthusiasts.
